脐带血来源 CAR-NK 细胞：肿瘤免疫治疗的新兴即用型平台

Umbilical cord blood-derived CAR-NK cells: an emerging off-the-shelf platform for cancer immunotherapy.

PARP 抑制剂联合安罗替尼作为卵巢癌装甲 CAR-T 细胞的桥接治疗可增强浸润与抗肿瘤疗效

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

IL-15 增强间皮素和 CD70 CAR NK 细胞在 PDAC 中的效力，双靶向未带来额外获益

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.

微流控 T-Chip 实现用于 CAR-T 细胞生产的血液制品一步临床规模 T 细胞纯化

Microfluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturing.

MSLN-CAR-T 细胞中开关受体 PD1/IL15Rβ 的表达克服实体瘤中的 PD1/PDL1 信号

Expression of the switch receptor PD1/IL15Rβ in MSLN-CAR-T cells overcomes PD1/PDL1 signaling in solid tumors.

工程化靶向近膜区的抗间皮素 CAR-T 细胞：一种可抵抗脱落抗原的新型结合分子以增强对卵巢癌和胰腺癌的疗效

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian an

分泌 anti-PD-L1 scFv 的新一代间皮素靶向 CAR-T 细胞用于强效免疫治疗 3D 患者来源结直肠癌类器官

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer org

最后，我们的 14 天离体 CRC-PDOs/CAR-T 平台为实体瘤中的肿瘤相关抗原验证、简化的 PDO 分离、自体 CAR-T 细胞毒性测试以及个性化免疫治疗优化提供了一种有前景的快速转化工具。

靶向 MUC16 的膀胱内间皮素 CAR-T 细胞在临床前模型中有效控制膀胱癌

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

寻找 AML 中安全有效的 CAR-T 靶点

The search for safe and effective CAR-T targets in AML.